Your session is about to expire
← Back to Search
Nonsteroidal Anti-inflammatory Drug
Aspirin for Prophylaxis of Preeclampsia (APROACH-PK Trial)
Phase 1 & 2
Waitlist Available
Led By Rupsa C Boelig, MD
Research Sponsored by Thomas Jefferson University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Singleton pregnancy
Plan to take 81mg aspirin due to high risk history (below), but not yet initiated
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hour
Awards & highlights
APROACH-PK Trial Summary
This trial will study how a pregnant woman's body processes and responds to medication during different stages of pregnancy.
Eligible Conditions
- Prophylaxis of Preeclampsia
APROACH-PK Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowAPROACH-PK Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 hour
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hour
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
PFA-100
salicylic acid level
serum thromboxane
Secondary outcome measures
Urinary thromboxane
APROACH-PK Trial Design
1Treatment groups
Experimental Treatment
Group I: AspirinExperimental Treatment1 Intervention
81mg aspirin daily
Find a Location
Who is running the clinical trial?
Thomas Jefferson UniversityLead Sponsor
443 Previous Clinical Trials
145,480 Total Patients Enrolled
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
1,953 Previous Clinical Trials
2,660,666 Total Patients Enrolled
March of DimesOTHER
22 Previous Clinical Trials
30,278 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger